Search Results
Aug 11, 2026, 08:00 ET Novo Nordisk's Awiqli®, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US
https://doi.org/10.1007/s13300-022-01222-2Rosenstock J, Gowda A, Liang B. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023;389(16):1533. doi:10.1056/NEJMc2310221Philis-Tsimikas
More news about: Novo Nordisk
Aug 11, 2026, 08:00 ET Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
https://www.census.gov/quickfacts [6] U.S. Census Bureau. B02001: Race, 2022 American Community Survey 1-Year Estimates. U.S. Department of Commerce; 2022. Accessed Aug. 4, 2026.
More news about: Sentynl Therapeutics
Aug 11, 2026, 07:55 ET Syra Health Achieves 23% Revenue Growth, Improves Gross Margin to 44.5% in Second Consecutive Profitable Quarter
Convertible class B common stock, $0.001 par value, 5,000,000 shares authorized, 350,000 and 600,000 shares issued
More news about: Syra Health
Aug 11, 2026, 07:54 ET EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing
-- EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss company's USD 152 million Series B financingThe financing will support the initiation of the global Phase 3 HEROIC study evaluating engasertib, a potential first treatment for
More news about: EQT
Aug 11, 2026, 07:30 ET Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
("pCR") in patients receiving INT230-6 in Cohort A and a 42% pCR in patients receiving the SOC alone (Cohort B). There was also a 44% reduction in grade 3 adverse events in Cohort A compared with Cohort B and fewer immune-related adverse events when INT230-6 was added prior to the immunochemotherapy. Capital
More news about: Intensity Therapeutics Inc.
Aug 11, 2026, 07:24 ET Chandigarh University Students' 'Green Heart' Wins NASSCOM's Best Startup Award, Bags ₹5 Lakh Grant to Transform Farming with AI, Satellites & IoT
Chandigarh University students including Garvit Saluja (Founder), Aditya Bhandari and Prakhar Nautiyal (both Co-Founders), all final-year students of B Tech in Computer Science and Engineering (Artificial Intelligence and Machine Learning (AIML)), this tech-enabled platform 'GreenHeart' has been designed
More news about: Chandigarh University
Aug 11, 2026, 07:07 ET EMBC Investor Announcement: Embecta Sued on behalf of Investors to Recover Losses after Insulin Pen Issues Lead to 57% Stock Drop
until August 17, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Embecta common stock. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Aug 11, 2026, 07:07 ET PNR Investor Announcement: Pentair Sued on behalf of Investors to Recover Losses after Pool Inventory Issues Lead to 15% Stock Drop
until October 2, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Pentair securities. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Aug 11, 2026, 07:07 ET RXT Investor Announcement: Rackspace Sued on behalf of Investors to Recover Losses after AI Effort Issues Lead to 33% Stock Drop
until September 28, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Rackspace securities. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Aug 11, 2026, 07:07 ET GTM Investor Announcement: ZoomInfo Sued on behalf of Investors to Recover Losses after AI Integration Issues Lead to 33% Stock Drop
until August 24, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in ZoomInfo securities. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Aug 11, 2026, 07:07 ET INTU Investor Announcement: Intuit Sued on behalf of Investors to Recover Losses after Pricing Issues Lead to 20% Stock Drop
until September 8, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Intuit securities. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Aug 11, 2026, 07:07 ET PRCT Investor Announcement: PROCEPT BioRobotics Sued on behalf of Investors to Recover Losses after Artificially Inflated Revenue Leads to 18% Stock Drop
until September 22, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Procept common stock. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Aug 11, 2026, 07:07 ET BTU Investor Announcement: Peabody Sued on behalf of Investors to Recover Losses after Mine Production Issues Lead to 10% Stock Drop
until August 24, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Peabody common stock. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Aug 11, 2026, 07:07 ET CAPR Investor Announcement: Capricor Therapeutics Sued on behalf of Investors to Recover Losses after Clinical Data Leads to 64% Stock Drop
until September 28, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Capricor securities. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Aug 11, 2026, 07:07 ET PLNT Investor Announcement: Planet Fitness Sued on behalf of Investors to Recover Losses after Membership Growth Issues Lead to 31% Stock Drop
until September 14, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Planet Fitness common stock. The class action is pending in the U.S. District
More news about: Bleichmar Fonti & Auld LLP
Aug 11, 2026, 07:07 ET HUBG Investor Announcement: Hub Group Sued on behalf of Investors to Recover Losses after Financial Restatements Lead to 18% Stock Drop
until August 28, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Hub Group securities. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Aug 11, 2026, 07:00 ET Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
$152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and DroiaProvides
More news about: Vaderis Therapeutics AG
Aug 11, 2026, 07:00 ET Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
$152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and DroiaProvides
More news about: Vaderis Therapeutics AG
Aug 11, 2026, 07:00 ET MCDANIELS MARKETING CELEBRATES 60 YEARS IN BUSINESS AMID RECORD GROWTH
agriculture, finance, B2B, B2C,
More news about: McDaniels Marketing
Aug 11, 2026, 07:00 ET MyFBAPrep Earns Elite Status After Being Named to the 2026 Inc. 5000 List for the Fourth Consecutive Year
Kingdom, mainland Europe, and Australia, MyFBAPrep supports Amazon FBA prep, direct-to-consumer fulfillment, retail and wholesale distribution, and B2B logistics.Inc. 5000 List MethodologyCompanies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2022
More news about: MyFBAPrep
Aug 11, 2026, 07:00 ET Traditional Medicinals Earns a Spot on the 2026 Inc. 5000 for the First Time
ethical, sustainable business. In service of this mission, Traditional Medicinals now produces more than 60 teas, lozenges, and capsules as a Certified B Corporation and has invested more than $20 million in farming and wild-collecting communities around the globe over the past decade. Those community partners,
More news about: Traditional Medicinals
Aug 11, 2026, 07:00 ET LX Pantos Strengthens Global ESG Leadership Through Its 2026 Sustainability Report
third-party assurance agency verified the report for accuracy and reliability.In 2025, LX Pantos also earned a Bronze rating from EcoVadis, a B rating from the Carbon Disclosure Project (CDP), LEED Gold certification for the MegaWise Cheongna Center, and an A+ rating under the Regional Social
More news about: LX Pantos
Aug 11, 2026, 07:00 ET A LX Pantos reafirma sua liderança global em ESG com a publicação de seu Relatório de Sustentabilidade de 2026
verificou a precisão e a confiabilidade do relatório.Em 2025, o LX Pantos também conquistou a classificação Bronze da EcoVadis, a classificação B do Carbon Disclosure Project (CDP), a certificação LEED Gold para o MegaWise Cheongna Center e a classificação A+ no âmbito do Sistema Regional de Reconhecimento
More news about: LX Pantos
Aug 11, 2026, 07:00 ET LX Pantos refuerza su liderazgo mundial en materia de ESG a través de su Informe de Sostenibilidad 2026
independiente comprobó la exactitud y confiabilidad del informe.En 2025, LX Pantos también obtuvo una calificación de Bronce de EcoVadis, una calificación B del Carbon Disclosure Project (CDP), la certificación LEED Oro para el MegaWise Cheongna Center y una calificación A+ en el marco del Sistema Regional
More news about: LX Pantos
Aug 11, 2026, 07:00 ET Landmark Peer-Reviewed Study Validates New Knee Brace Technology for Most Common Knee Condition
patellofemoral joint."Patellofemoral unloading remains an unfamiliar concept for many clinicians," said study co-author and orthopaedic surgeon Adam B. Yanke, M.D., Ph.D. "It took time for me to fully appreciate its potential, and it was only after using the brace in clinical practice that I began to
More news about: Icarus Medical